# Understanding the Technical Profile of D-JNKI-1 Peptide
In the specialized field of biochemical research, few compounds have garnered as much interest for pathway-specific studies as d-jnki-1 peptide. As an enthusiast of peptide research and a frequent observer of molecular signaling modulation, I have spent significant time reviewing the structural and functional nuances of this sophisticated molecule. This overview is intended for those interested in the technical specifications and the structural composition of this un Feb 12, 2026 · Brimapitide (AM-111, D-JNKI-1) is a synthetic 31-amino acid cell-penetrating peptide … ique research tool.
The D-JNKI-1 peptide, often referred to in laboratory literature by its scientific identifiers such as d jnki 1 am 111 or simply d jnki 1, represents a masterclass in peptide engineering. Structurally, it is a 31-amino acid chimeric peptide designed for specific intracellular applications.
What makes this compound particularly effective in research settings is its dual-domain design:
* The TAT Domain: A 10-amino acid sequence derived from the HIV-1 TAT protein, which facilitates cell-penetrating capabilities.
* The JBD Sequence: A 20-amino acid "minimal" c-Jun N-terminal kinase (JNK) binding domain.
This synthesis allows the molecule to cross cellular membranes effectively, a hurdle that often limits the efficacy of many larger biological research molecules.
Mechanism of Action: The MAPK-JNK Pathway
The primary utility of D-JNKI-1 lies in its ability to inhibit the c-Jun N-terminal kinase (JNK) signaling pathway, a subset of the Mitogen-Activated Protein Kinase (MAPK) cascades. By sequestering the interaction between JNK and its downstream targets, this peptide acts as a precision tool for observing how cellular stress responses are mediated.
Historically, this peptide (also identified as Brimapitide, XG-102, or AM-111) has demonstrated high specificity in scientific models, allowing researchers to isolate JNK-dependent mechanisms without the broad, non-specific interference often caused by small-molecule inhibitors.
Essential Data for Research Standardization
When analyzing the efficacy of such a peptide Introduction D-JNKI-1, a cell-permeable peptide inhibitor, has garnered significant attention for its therapeutic potential in a range of … , resear D-JNKI-1 acetate - JNK Inhibitory Peptide | APExBIO ch Preclinical and clinical otoprotective applications of cell-penetrating ers must consider its physical properties. It is often provided as an acetate salt, which preserves its stability and solubility for experimental use.
Key verifiable identifiers for those documenting their supply include:
* CAS D-JNKI-1: A Technical Review of a JNK-Inhibiting Peptide for Number: 1445179-97-4
* Molecular Formula: C164H Executive Summary D-JNKI-1, also known as AM-111, XG-102, or by its chemical name Brimapitide, is a synthetic, cell-permeable … 285N65O41
* Common Synonyms: Brimapitide, AM-111, XG-102
The consistent results reported across various peer-reviewed databases—such as PubChem and major chemical suppliers—underscore the importance of purity. In my experience, ensuring the use of high-analytical-grade material is paramount, as the integrity of the 31-amino acid chain is what dictates its potent cell-permeable characteristic.
Personal Perspective on Peptide Research
Evaluating compounds like the D-JNKI-1 peptide requires a rigorous adherence to protocol. It is not merely a re D-JNKI-1 acetate - JNK Inhibitory Peptide | APExBIO agent; it is a structural intervention tool. My interest stems from the elegance of h D-JNKI-1 (30 aa) is a chimeric peptide startingwitha10aaTATtransportersequence,followedbya20aaminimalJBDsequencefrom the … ow the TAT-JBD fusion circumvents traditional transport limitations. For those of us who track the evolution of inhibitory peptides, it is clear that the development of specialized cell-penetrating agents has unlocked new avenues for examining intracellular signaling in a variety of murine and cell-culture models.
When utilizing this peptide, one must always prioritize proper storage and handling, typically involving strictly controlled temperatures (often -20°C or lower) and avoidance of freeze-thaw cycles, which can degrade the peptide bonds. The rigor of your methodology in preparing the peptide, including proper reconstitution in a compatible buffer, is often the deciding factor in the success of any binding affinity study.
As research continues to unfold regarding the MAPK-JNK pathway, the role of D-JNKI-1 remains central. Its classification as a cell-permeable inhibitor is not just a label—it is the functional cornerstone that makes it an indispensable asset in modern laboratory investigations. Always ensure that your research aligns with current institutional protocols for handling synthetic peptides to maintain the highest standard of scientific integrity.
# Understanding the Technical Profile of D-JNKI-1 Peptide
In the specialized field of biochemical research, few compounds have garnered as much interest for pathway-specific studies as d-jnki-1 peptide. As an enthusiast of peptide research and a frequent observer of molecular signaling modulation, I have spent significant time reviewing the structural and functional nuances of this sophisticated molecule. This overview is intended for those interested in the technical specifications and the structural composition of this un Feb 12, 2026 · Brimapitide (AM-111, D-JNKI-1) is a synthetic 31-amino acid cell-penetrating peptide … ique research tool.
The D-JNKI-1 peptide, often referred to in laboratory literature by its scientific identifiers such as d jnki 1 am 111 or simply d jnki 1, represents a masterclass in peptide engineering. Structurally, it is a 31-amino acid chimeric peptide designed for specific intracellular applications.
What makes this compound particularly effective in research settings is its dual-domain design:
* The TAT Domain: A 10-amino acid sequence derived from the HIV-1 TAT protein, which facilitates cell-penetrating capabilities.
* The JBD Sequence: A 20-amino acid "minimal" c-Jun N-terminal kinase (JNK) binding domain.
This synthesis allows the molecule to cross cellular membranes effectively, a hurdle that often limits the efficacy of many larger biological research molecules.
Mechanism of Action: The MAPK-JNK Pathway
The primary utility of D-JNKI-1 lies in its ability to inhibit the c-Jun N-terminal kinase (JNK) signaling pathway, a subset of the Mitogen-Activated Protein Kinase (MAPK) cascades. By sequestering the interaction between JNK and its downstream targets, this peptide acts as a precision tool for observing how cellular stress responses are mediated.
Historically, this peptide (also identified as Brimapitide, XG-102, or AM-111) has demonstrated high specificity in scientific models, allowing researchers to isolate JNK-dependent mechanisms without the broad, non-specific interference often caused by small-molecule inhibitors.
Essential Data for Research Standardization
When analyzing the efficacy of such a peptide Introduction D-JNKI-1, a cell-permeable peptide inhibitor, has garnered significant attention for its therapeutic potential in a range of … , resear D-JNKI-1 acetate - JNK Inhibitory Peptide | APExBIO ch Preclinical and clinical otoprotective applications of cell-penetrating ers must consider its physical properties. It is often provided as an acetate salt, which preserves its stability and solubility for experimental use.
Key verifiable identifiers for those documenting their supply include:
* CAS D-JNKI-1: A Technical Review of a JNK-Inhibiting Peptide for Number: 1445179-97-4
* Molecular Formula: C164H Executive Summary D-JNKI-1, also known as AM-111, XG-102, or by its chemical name Brimapitide, is a synthetic, cell-permeable … 285N65O41
* Common Synonyms: Brimapitide, AM-111, XG-102
The consistent results reported across various peer-reviewed databases—such as PubChem and major chemical suppliers—underscore the importance of purity. In my experience, ensuring the use of high-analytical-grade material is paramount, as the integrity of the 31-amino acid chain is what dictates its potent cell-permeable characteristic.
Personal Perspective on Peptide Research
Evaluating compounds like the D-JNKI-1 peptide requires a rigorous adherence to protocol. It is not merely a re D-JNKI-1 acetate - JNK Inhibitory Peptide | APExBIO agent; it is a structural intervention tool. My interest stems from the elegance of h D-JNKI-1 (30 aa) is a chimeric peptide startingwitha10aaTATtransportersequence,followedbya20aaminimalJBDsequencefrom the … ow the TAT-JBD fusion circumvents traditional transport limitations. For those of us who track the evolution of inhibitory peptides, it is clear that the development of specialized cell-penetrating agents has unlocked new avenues for examining intracellular signaling in a variety of murine and cell-culture models.
When utilizing this peptide, one must always prioritize proper storage and handling, typically involving strictly controlled temperatures (often -20°C or lower) and avoidance of freeze-thaw cycles, which can degrade the peptide bonds. The rigor of your methodology in preparing the peptide, including proper reconstitution in a compatible buffer, is often the deciding factor in the success of any binding affinity study.
As research continues to unfold regarding the MAPK-JNK pathway, the role of D-JNKI-1 remains central. Its classification as a cell-permeable inhibitor is not just a label—it is the functional cornerstone that makes it an indispensable asset in modern laboratory investigations. Always ensure that your research aligns with current institutional protocols for handling synthetic peptides to maintain the highest standard of scientific integrity.